Mumbai, Nov. 14 -- Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose ...
New Delhi, Nov 14 (PTI) Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative ...
Leuprolide acetate for injection is used to treat the symptoms associated with advanced prostate cancer by way of palliative treatment of advanced prostatic cancer. Aurobindo’s subsidiary, Eugia ...
The Food and Drug Administration has cleared Amneal’s leuprolide acetate for injection, which is indicated in the palliative treatment of advanced prostatic cancer. “We are making tremendous progress ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), an integrated essential medicines company, announced Wednesday that it has received Abbreviated New Drug Application or ANDA approval from the U.S.
Combined mTOR and AKT inhibition in renal cell carcinoma (RCC). Background: Leuprolide acetate is a synthetic analog of gonadotropin hormone-releasing hormone (GnRH-a) that reduces serum testosterone ...
The prescribed dosage for Lupron Depot (leuprolide acetate) may vary depending on certain factors, including the condition you’re using the drug to treat and how your body responds to the drug. Lupron ...
Credit: Getty Images. Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist. Camcevi ® (leuprolide mesylate) 42mg injection ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results